<?xml version='1.0' encoding='utf-8'?>
<document id="14651665"><sentence text="Physicians' prescribing attitudes to combined therapy with statins and fibrates." /><sentence text="To assess the impact of a package insert revision and a drug-drug interaction warning embedded in a computerized prescription ordering system, on physicians' prescribing of concomitant statins and fibrates" /><sentence text="" /><sentence text="Data were obtained using a computerized prescription order entry system before and after administrative intervention advising of potentially adverse effects of this combined therapy" /><sentence text=" The number of prescriptions for statins and fibrates were counted monthly from January 1998 to June 2002 at the National Cardiovascular Center (NCVC)" /><sentence text=" Counting was based on information from a prescription database file compiled from a computerized order entry system" /><sentence text=" The total number of prescriptions and frequency of requests for statins and fibrates were compared with the timing of either package insert revision or introduction of the warning on a computerized prescription ordering system" /><sentence text=" In addition, laboratory testing of renal function using serum creatinine (Scr) assays in patients treated with combined statins and fibrates was obtained from medical records at two stages during the study period (stage 1, January 1998 to June 1998; stage 2, January 2002 to June 2002)"><entity charOffset="63-73" id="DDI-PubMed.14651665.s8.e0" text="creatinine" /><entity charOffset="75-78" id="DDI-PubMed.14651665.s8.e1" text="Scr" /><pair ddi="false" e1="DDI-PubMed.14651665.s8.e0" e2="DDI-PubMed.14651665.s8.e0" /><pair ddi="false" e1="DDI-PubMed.14651665.s8.e0" e2="DDI-PubMed.14651665.s8.e1" /></sentence><sentence text="" /><sentence text="There were 204 prescriptions for concomitant statins and fibrates at the beginning and 50 prescriptions at end of the study period" /><sentence text=" The number of prescriptions began to decrease in the latter half of 1999 with the percentage of concomitant use of statins and fibrates showing an evident downward trend from January 2001" /><sentence text=" This acceleration in the downward trend coincided with the introduction of the computerized warning message" /><sentence text=" Scr levels were measured in 43"><entity charOffset="1-3" id="DDI-PubMed.14651665.s13.e0" text="Scr" /></sentence><sentence text="8% of patients in stage 1 and in 48" /><sentence text="3% of patients in stage 2 in the past month" /><sentence text=" The percentage of patients having Scr levels measured in the past 6 months was 85"><entity charOffset="35-37" id="DDI-PubMed.14651665.s16.e0" text="Scr" /></sentence><sentence text="3% in stage 1 and 84" /><sentence text="5% in stage 2" /><sentence text=" There was no significant difference in the percentages of patients whose Scr levels had been measured between the two stages"><entity charOffset="74-76" id="DDI-PubMed.14651665.s19.e0" text="Scr" /></sentence><sentence text="" /><sentence text="Revision of package inserts concerning combined therapy of statins and fibrates led to physicians' prescribing fewer of these combinations" /><sentence text=" A warning message displayed on a computerized prescription order entry system accentuated this effect" /><sentence text="" /></document>